Effect of Plasmacytoid Dendritic Cell Dose in Grafts on CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation.
10.19746/j.cnki.issn.1009-2137.2023.04.039
- Author:
Di YAO
1
;
Yuan-Yuan TIAN
1
;
Jun LU
1
;
Pei-Fang XIAO
1
;
Jing LING
1
;
De-Fei ZHENG
1
;
Jing GAO
1
;
Li-Yan FAN
1
;
Jia-Jia ZHENG
1
;
Jie LI
1
;
Shao-Yan HU
2
Author Information
1. Department of Hematology, Children's Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China.
2. Department of Hematology, Children's Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China.E-mail: hushaoyan@suda.edu.cn.
- Publication Type:Journal Article
- Keywords:
allogeneic hematopoietic stem cell transplantation;
cell dose;
cytomegalovirus;
graft;
plasmacytoid dendritic cell
- MeSH:
Child;
Humans;
Retrospective Studies;
Graft vs Host Disease/complications*;
Cytomegalovirus Infections;
Hematopoietic Stem Cell Transplantation/adverse effects*;
Dendritic Cells
- From:
Journal of Experimental Hematology
2023;31(4):1184-1191
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the correlation between plasmacytoid dendritic cell (pDC) dose in grafts and the occurrence of cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
METHODS:The clinical data of 80 children who received allo-HSCT in Children's Hospital of Soochow University from August 20, 2020 to June 11, 2021 were retrospectively analyzed. Proportions of DC subsets and T-cell subsets in grafts were detected by flow cytometry in order to calculate infused cell dose of each cell. Weekly monitoring of CMV-DNA copies in peripheral blood for each child were performed after transplantation. The last follow-up date was December 31, 2021.
RESULTS:All the children gained hematopoietic reconstitution. CMV infection was observed in 51 children (63.8%±5.4%) within the first 100 days after transplantation, including 2 cases developing CMV disease. Univariate analysis indicated that infused doses of DC and pDC were significantly associated with CMV infection within 100 days after allo-HSCT (P <0.05). Multivariate analysis indicated that a high dose infusion of pDC was an independent protective factor for CMV infection within 100 days after allo-HSCT (P <0.05). By the end of follow-up, 7 children died of transplantation-related complications, including 2 deaths from CMV disease, 2 deaths from extensive chronic graft-versus-host disease, and 3 deaths from capillary leak syndrome. The overall survival rate was 91.2%.
CONCLUSION:The pDC in grafts may be associated with early infection of CMV after allo-HSCT, while a high infused pDC dose may serve as a protective factor for CMV infection after transplantation.
